RARECast: Incentives Boost Innovation in Rare Disease Therapies

June 19, 2015

Patent filings in the area of rare diseases suggest government incentives have worked to spur innovation, according to a new report from the international intellectual property firm Marks & Clerk. The report examines patent filings in the areas of rare diseases, antibiotics, and vaccines. We spoke to Gareth Williams, partner and European patent attorney with Marks & Clerk, about the report, the role Big Pharma is playing, and some surprises on the list of top filers of rare disease related patents.

RARECast is a weekly series by Daniel S. Levine. Levine is an award-winning business journalist who has reported on the life sciences, economic development, and business policy issues throughout his 25-year career. He founded Levine Media Group in 2013, which produces The Bio Report and RARECast podcasts. Read his full bio here. 

Stay Connected

Sign up for updates straight to your inbox.